Kelun-Biotech says China regulator accepts NDA for lunbotinib in RET fusion-positive NSCLC

  • Sichuan Kelun-Biotech’s China drug regulator accepted an NDA for lunbotinib fumarate to treat adult RET fusion-positive advanced or metastatic NSCLC.
  • Filing followed pivotal Phase II data shown at ASCO 2026, with IRC-assessed ORR of 81.3% in treatment-naïve patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605292329PR_NEWS_USPR_____CN71870) on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.